Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Argos Therapeutics, an immunotherapy company, has closed the second and final tranche of a $35.2 million series C financing from a top-tier, international syndicate of new and existing investors. The first tranche was completed in April 2008.
Subscribe to our email newsletter
As previously announced, the financing was led by TVM Capital and included participation from new investors Mizuho Capital, Morningside Group and Japan Asia Investment Co.
Existing Argos investors Lumira Capital, Forbion Capital Partners, CDP Capital, Intersouth Partners, Aurora Capital, and GeneChem also participated in the round, with several of these investors participating significantly above their pro rata share. Kyowa Hakko Kirin, which has an on-going worldwide collaboration with Argos, also participated in this financing.
Timothy Trost, CFO of Argos, said: “Proceeds from the second tranche of the series C will be used to fund the company’s ongoing Phase II trials for our Arcelis immunotherapy candidates in renal cell carcinoma and HIV. These resources will also support the further development of Argos’s CD83 protein immunology program into an initial human clinical trial in transplantation.”